Jagsonpal Pharmaceuticals Limited - Asset Resilience Ratio
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has an Asset Resilience Ratio of 49.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read JAGSNPHARM total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Jagsonpal Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. See Jagsonpal Pharmaceuticals Limited shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Jagsonpal Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Jagsonpal Pharmaceuticals Limited stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs1.47 Billion | 49.0% |
| Total Liquid Assets | Rs1.47 Billion | 49.00% |
Asset Resilience Insights
- Very High Liquidity: Jagsonpal Pharmaceuticals Limited maintains exceptional liquid asset reserves at 49.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jagsonpal Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare Jagsonpal Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Jagsonpal Pharmaceuticals Limited (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Jagsonpal Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 42.23% | Rs1.18 Billion ≈ $12.71 Million |
Rs2.78 Billion ≈ $30.09 Million |
-20.04pp |
| 2024-03-31 | 62.27% | Rs1.35 Billion ≈ $14.62 Million |
Rs2.17 Billion ≈ $23.48 Million |
+3.31pp |
| 2023-03-31 | 58.96% | Rs1.15 Billion ≈ $12.43 Million |
Rs1.95 Billion ≈ $21.08 Million |
+30.61pp |
| 2022-03-31 | 28.35% | Rs477.64 Million ≈ $5.17 Million |
Rs1.68 Billion ≈ $18.22 Million |
-9.52pp |
| 2021-03-31 | 37.88% | Rs621.94 Million ≈ $6.73 Million |
Rs1.64 Billion ≈ $17.76 Million |
+8.57pp |
| 2020-03-31 | 29.30% | Rs430.64 Million ≈ $4.66 Million |
Rs1.47 Billion ≈ $15.89 Million |
+6.24pp |
| 2019-03-31 | 23.06% | Rs313.12 Million ≈ $3.39 Million |
Rs1.36 Billion ≈ $14.68 Million |
+16.59pp |
| 2018-03-31 | 6.47% | Rs83.98 Million ≈ $908.23K |
Rs1.30 Billion ≈ $14.04 Million |
-14.95pp |
| 2017-03-31 | 21.42% | Rs305.53 Million ≈ $3.30 Million |
Rs1.43 Billion ≈ $15.42 Million |
-- |
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more